title: [CD28 and CTLA-4 costimulatory molecules expression on T lymphocytes and NK cells in nonallergic bronchial asthma].
abstract: The aim of the study was to assess the role of costimulatory molecules in pathogenesis of nonallergic bronchial asthma.
  
  
  METHODS
  The studied group consisted of 30 patients with nonallergic asthma, 24 with nonallergic asthma and recurrent respiratory tract infections and 20 healthy controls.
  
  
  RESULTS
  In nonstimulated and lipopolysaccharide (LPS) stimulated cultures of control group the mean value of CD16+ + 56+ CD28+ subpopulation were significantly decreased compared to values in both types of asthma. Similar dependence was observed in cultures of asthmatic patients with infection and healthy person, stimulated with IL-15 and in CD4+CD28+, CD8 +CD28+ and NKCD28+ cultures from all studied groups, stimulated with LPS plus IL-15. In nonallergic asthma and infection asthma mean values of CD4 +CD152+ and CD16+ +CD56 +CD152+ from nonstimulated and IL-15 stimulated cultures were significantly increased compared to analogical values in control group.
  
  
  CONCLUSIONS
  The results of our studies suggest that in nonallergic asthma the disturbed expression of costimulatory molecules may play an important role in pathomechanism of disease.
authors.affiliation: Akademia Medyczna w Biatymstoku, Zaktad Alergologii Dziecigcej. rutkowski@csk.pl
authors.forename: Ryszard
authors.initials: R
authors.lastname: Rutkowski
authors.forename: Anna
authors.initials: A
authors.lastname: Stasiak-Barmuta
authors.forename: Tadeusz
authors.initials: T
authors.lastname: Moniuszko
authors.forename: Danuta
authors.initials: D
authors.lastname: Rutkowska-Rogacz
authors.forename: Marzanna
authors.initials: M
authors.lastname: Woińska
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Rutkowski
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Sidorczuk
mesh_terms: D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000328:Adult; D000420:Albuterol / Q000031:analogs & derivatives / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000276:immunology*; D001249:Asthma / Q000188:drug therapy / Q000276:immunology*; D018106:CD28 Antigens / Q000276:immunology*; D060908:CTLA-4 Antigen; D005260:Female; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D000068299:Salmeterol Xinafoate; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000318:Adrenergic beta-Agonists; D000893:Anti-Inflammatory Agents; D015703:Antigens, CD; D000943:Antigens, Differentiation; D018106:CD28 Antigens; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D000068299:Salmeterol Xinafoate; D000420:Albuterol; D011241:Prednisone